ConductScience.org, home

Paper378369

Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations.

Davis HL and 1 other. Cancer Treat Rep, 1979. Cited by 88 papers, by iCite.

Cite this record

ConductScience Library. Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations. Papers, record 378369. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/378369

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1979
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S., Review
PubMed
Citations, by iCite
88
iCite
Relative citation ratio, by iCite
3.56
iCite
Revised in PubMed
2013-11-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Davis HLH L
2Davis TET E

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DaunorubicinMajor topic
DoxorubicinMajor topic
NeoplasmsMajor topic
Breast Neoplasms
Drug Therapy, Combination
Hodgkin Disease
Humans
Leukemia
Lymphoma
Sarcoma
Soft Tissue Neoplasms

Source PubMed

Download CSV of topics

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 88 citations.

PMIDTitleJournalYearIn PapersSource
38700665Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis.Cardiovasc Toxicol2024https://conductscience.org/library/papers/38700665PubMed
36816668Tandem Protocol of Hexahydroquinoline Synthesis Using [H2-DABCO][HSO4]2 Ionic Liquid as a Green Catalyst at Room Temperature.ACS Omega2023https://conductscience.org/library/papers/36816668PubMed
24277182Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites.Pharm Res1984https://conductscience.org/library/papers/24277182PubMed
23508666N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence.Eur J Clin Pharmacol2013https://conductscience.org/library/papers/23508666PubMed
18451141Genetic variants contributing to daunorubicin-induced cytotoxicity.Cancer Res2008https://conductscience.org/library/papers/18451141PubMed
17545624Mapping genes that contribute to daunorubicin-induced cytotoxicity.Cancer Res2007https://conductscience.org/library/papers/17545624PubMed
7425613Biosynthesis of daunorubicin glycosides: role of epsilon-rhodomycinone.Antimicrob Agents Chemother1980https://conductscience.org/library/papers/7425613PubMed
6961377Anthracycline cardiomyopathy.Pediatr Cardiol1982https://conductscience.org/library/papers/6961377PubMed
6819097Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6819097PubMed
6574828A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6574828PubMed
6189661Clinical pharmacokinetics of commonly used anticancer drugs.Clin Pharmacokinet1983https://conductscience.org/library/papers/6189661PubMed
3860797Aspects of the chemical stability of doxorubicin and seven other anthracyclines in acidic solution.Pharm Weekbl Sci1985https://conductscience.org/library/papers/3860797PubMed
3730255Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention.Br J Cancer1986https://conductscience.org/library/papers/3730255PubMed
3698178A rapid chromatographic procedure for the determination of adriamycin, daunomycin and their 13-OH metabolites adriamycinol and daunomycinol.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3698178PubMed
3555940Pharmacokinetics of anticancer drugs in children.Clin Pharmacokinet1987https://conductscience.org/library/papers/3555940PubMed
3520474Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.Pharm Weekbl Sci1986https://conductscience.org/library/papers/3520474PubMed
3459509The in vitro effects and cross-resistance patterns of some novel anthracyclines.Br J Cancer1986https://conductscience.org/library/papers/3459509PubMed
3359560Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3359560PubMed
3358904Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line.Br J Cancer1988https://conductscience.org/library/papers/3358904PubMed
3223881SEM observations on the effect of anthracycline drugs on cultured newborn rat cardiomyocytes.Basic Res Cardiol1988https://conductscience.org/library/papers/3223881PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/378369

GET https://conductscience.org/api/papers/v1/378369/cited_by?page=2